2x23: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2x23.png|left|200px]]
-<!--
+==crystal structure of M. tuberculosis InhA inhibited by PT70==
-The line below this paragraph, containing "STRUCTURE_2x23", creates the "Structure Box" on the page.
+<StructureSection load='2x23' size='340' side='right'caption='[[2x23]], [[Resolution|resolution]] 1.81&Aring;' scene=''>
-You may change the PDB parameter (which sets the PDB file loaded into the applet)
+== Structural highlights ==
-or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+<table><tr><td colspan='2'>[[2x23]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis_H37Rv Mycobacterium tuberculosis H37Rv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2X23 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2X23 FirstGlance]. <br>
-or leave the SCENE parameter empty for the default display.
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.807&#8491;</td></tr>
--->
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=NAD:NICOTINAMIDE-ADENINE-DINUCLEOTIDE'>NAD</scene>, <scene name='pdbligand=TCU:5-HEXYL-2-(2-METHYLPHENOXY)PHENOL'>TCU</scene></td></tr>
-{{STRUCTURE_2x23|  PDB=2x23  |  SCENE=  }}
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2x23 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2x23 OCA], [https://pdbe.org/2x23 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2x23 RCSB], [https://www.ebi.ac.uk/pdbsum/2x23 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2x23 ProSAT]</span></td></tr>
+</table>
+== Function ==
+[https://www.uniprot.org/uniprot/INHA_MYCTU INHA_MYCTU]
+== Evolutionary Conservation ==
+[[Image:Consurf_key_small.gif|200px|right]]
+Check<jmol>
+  <jmolCheckbox>
+    <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/x2/2x23_consurf.spt"</scriptWhenChecked>
+    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
+    <text>to colour the structure by Evolutionary Conservation</text>
+  </jmolCheckbox>
+</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=2x23 ConSurf].
+<div style="clear:both"></div>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for the development of novel drugs against tuberculosis, a disease that kills more than two million people each year. InhA is the target of the current first line drug isoniazid for the treatment of tuberculosis infections. Compounds that directly target InhA and do not require activation by the mycobacterial catalase-peroxidase KatG are promising candidates for treating infections caused by isoniazid-resistant strains. Previously we reported the synthesis of several diphenyl ethers with nanomolar affinity for InhA. However, these compounds are rapid reversible inhibitors of the enzyme, and based on the knowledge that long drug target residence times are an important factor for in vivo drug activity, we set out to generate a slow onset inhibitor of InhA using structure-based drug design. 2-(o-Tolyloxy)-5-hexylphenol (PT70) is a slow, tight binding inhibitor of InhA with a K(1) value of 22 pm. PT70 binds preferentially to the InhA x NAD(+) complex and has a residence time of 24 min on the target, which is 14,000 times longer than that of the rapid reversible inhibitor from which it is derived. The 1.8 A crystal structure of the ternary complex between InhA, NAD(+), and PT70 reveals the molecular details of enzyme-inhibitor recognition and supports the hypothesis that slow onset inhibition is coupled to ordering of an active site loop, which leads to the closure of the substrate-binding pocket.
-===CRYSTAL STRUCTURE OF M. TUBERCULOSIS INHA INHIBITED BY PT70===
+A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.,Luckner SR, Liu N, am Ende CW, Tonge PJ, Kisker C J Biol Chem. 2010 May 7;285(19):14330-7. Epub 2010 Mar 3. PMID:20200152<ref>PMID:20200152</ref>
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-<!--
+</div>
-The line below this paragraph, {{ABSTRACT_PUBMED_20200152}}, adds the Publication Abstract to the page
+<div class="pdbe-citations 2x23" style="background-color:#fffaf0;"></div>
-(as it appears on PubMed at http://www.pubmed.gov), where 20200152 is the PubMed ID number.
--->
-{{ABSTRACT_PUBMED_20200152}}
-==About this Structure==
-[[2x23]] is a 4 chain structure of [[Enoyl-Acyl-Carrier Protein Reductase]] with sequence from [http://en.wikipedia.org/wiki/Mycobacterium_tuberculosis Mycobacterium tuberculosis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2X23 OCA].
 ==See Also==
-*[[Enoyl-Acyl-Carrier Protein Reductase]]
+*[[Enoyl-Acyl-Carrier Protein Reductase 3D structures|Enoyl-Acyl-Carrier Protein Reductase 3D structures]]
-*[[InhA]]
+== References ==
+<references/>
-==Reference==
+__TOC__
-<ref group="xtra">PMID:020200152</ref><references group="xtra"/>
+</StructureSection>
-[[Category: Mycobacterium tuberculosis]]
+[[Category: Large Structures]]
-[[Category: Ende, C W.Am.]]
+[[Category: Mycobacterium tuberculosis H37Rv]]
-[[Category: Kisker, C.]]
+[[Category: Kisker C]]
-[[Category: Liu, N.]]
+[[Category: Liu N]]
-[[Category: Luckner, S R.]]
+[[Category: Luckner SR]]
-[[Category: Tonge, P J.]]
+[[Category: Tonge PJ]]
-[[Category: Antibiotic resistance]]
+[[Category: Am Ende CW]]
-[[Category: Fatty acid biosynthesis]]
-[[Category: Lipid synthesis]]
-[[Category: Oxidoreductase]]